Abstract
Antacid treatments decrease the serum concentrations of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), although it is unknown whether antacids affect clinical outcomes. As cerebrospinal fluid concentrations of TKIs are much lower than serum concentrations, we hypothesized that this drug-drug interaction might affect the prognosis of patients with de novo brain metastases. This retrospective study evaluated 269 patients with EGFR-mutant non-small cell lung cancer (NSCLC) who had been diagnosed between December 2010 and December 2013, and had been treated using first-line first-generation EGFR-TKIs. Among these patients, we identified patients who concurrently used H2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) as antacids. Patients who exhibited >30% overlap between the use of TKIs and antacids were considered antacid users. Fifty-seven patients (57/269, 21.2%) were antacid users, and antacid use did not significantly affect progression-free survival (PFS; no antacids: 11.2 months, H2RAs: 9.4 months, PPIs: 6.7 months; p = 0.234). However, antacid use significantly reduced overall survival (OS; no antacids: 25.0 months, H2RAs: 15.5 months, PPIs: 11.3 months; p = 0.00...Continue Reading
References
Aug 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·William PaoHarold Varmus
Dec 18, 2004·Cancer Research·Takayuki KosakaTetsuya Mitsudomi
Sep 24, 2005·Clinical Lung Cancer·Alfonso GurpideJesus Garcia-Foncillas
Jun 15, 2007·Chest·Atsushi HoriikeMakoto Nishio
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
May 19, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Yosuke TogashiMichiaki Mishima
Oct 30, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephanie HeonBruce E Johnson
May 10, 2011·Clinical Lung Cancer·Chien-Hao LieMeng-Chih Lin
Oct 21, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Sumitra ThongprasertMasahiro Fukuoka
Jun 29, 2012·Clinical Pharmacology and Therapeutics·N R BudhaJ A Ware
Jul 19, 2012·Cancer Chemotherapy and Pharmacology·Yosuke TogashiMichiaki Mishima
Mar 5, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G ChenC You
Mar 28, 2013·Clinical Pharmacokinetics·Masahide FukudoToshiya Katsura
Aug 6, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·J F HiltonP A Bradbury
Aug 16, 2013·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Bing-Yen WangYung-Po Liaw
Mar 22, 2014·Molecular and Clinical Oncology·Yanming DengShunda Zhang
Sep 24, 2014·Clinical Lung Cancer·Michael P ChuMichael B Sawyer
Jan 16, 2015·The Lancet Oncology·James Chih-Hsin YangLecia V Sequist
Aug 12, 2015·PloS One·Yoshihito KogureKazuyoshi Imaizumi
Aug 28, 2015·PloS One·Yu-Mu ChenMeng-Chih Lin
Citations
Feb 5, 2019·Drugs & Aging·Manvi SharmaHolly M Holmes
Apr 25, 2020·Cancers·Alice IndiniMichele Ghidini
Jun 8, 2017·PloS One·Yu-Ping ChangMeng-Chih Lin
Dec 9, 2016·PloS One·Yu-Mu ChenMeng-Chih Lin
Jun 3, 2021·Journal of Personalized Medicine·Mario OcchipintiPaolo Marchetti
Jun 24, 2021·Tumori·Fausto Meriggi